A single arm, open label, clinical study of cryopreserved autologous CD34+ cells transduced with lentiviral vector containing human ARSA cDNA, for the treatment of early onset Metachromatic Leukodystrophy (MLD)
This study is designed for children with early-onset Metachromatic Leukodystrophy (MLD) to confirm the effectiveness and safety of a gene therapy called Libmeldy. MLD is a rare genetic condition that affects the nervous system. The treatment involves using the child's own cells, which are specially modified in the lab, to help produce a missing enzyme. Researchers will primarily be tracking improvements in a child's ability to move and function over a period of 24 months after receiving the gene therapy. They will also be looking at overall health, changes in the brain, how the body responds to the treatment, and any potential side effects. The aim is to understand if this therapy can significantly improve the lives of children with MLD.
At a glance
What is this study about?
This study is looking at a special type of treatment called gene therapy, known as Libmeldy, for children who have a condition called Metachromatic Leukodystrophy (MLD). MLD is a very rare and serious genetic disease that damages the brain and nervous system, affecting a child's ability to move, talk, and think over time. Currently, there are limited treatments available, so finding effective new options is extremely important.
The gene therapy in this study works by taking some of a child's own blood-forming stem cells, which are then carefully changed in a laboratory. These modified cells are designed to help the child's body produce a missing enzyme called Arylsulfatase A (ARSA). This enzyme is crucial for breaking down certain fats in the body; without it, these fats build up and cause damage to the brain and nerves.
The main goal of this study is to see how well Libmeldy helps children with MLD, especially in terms of their physical movement and overall health, over two years. Researchers will regularly check things like their ability to walk, stand, and balance. They will also monitor how the treatment affects their brain, nerves, and general well-being, while also keeping a very close eye on safety and any side effects. The hope is that this therapy can slow down or stop the progression of MLD and significantly improve the quality of life for these children.
Key takeaways
- This study is for children with early-onset Metachromatic Leukodystrophy (MLD).
- It's testing a gene therapy called Libmeldy to see if it helps with movement and health.
- The treatment involves a single infusion of specially modified cells.
- Children in the study will be closely monitored for at least two years.
- The main aim is to confirm the therapy's benefits and ensure its safety.
Who may be eligible?
This study is looking for children of all ages who have early-onset Metachromatic Leukodystrophy (MLD). This means the condition started at a young age.
Both boys and girls can take part in this study. The medical team will review each child's specific health details to make sure this treatment is suitable and safe for them. There might be other specific health requirements that your child needs to meet to be eligible for the study.
- Does your child have a confirmed diagnosis of early-onset Metachromatic Leukodystrophy (MLD)?
- Is your child within an age range that the medical team believes suitable for the study?
- Is your child's overall health stable enough for them to potentially receive this treatment?
- Have you discussed your child's full medical history with the study team?
- Are you able to commit to regular follow-up appointments over at least two years?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
Taking part in this study would involve several visits to the clinic over a period of at least two years after receiving the gene therapy. You would likely have an initial assessment period to determine if your child is suitable. The treatment itself involves a single infusion of the Libmeldy cells. After the treatment, there will be regular check-ups where doctors will assess your child's movement, nerve function, and overall health. This will involve physical examinations, possibly some scans of the brain (like an MRI), and blood tests. They will also look for any side effects. The total duration of follow-up for some aspects could extend beyond two years to ensure long-term safety and effectiveness.
Potential risks and benefits
Locations (1)
- —Italy
Common questions
What is MLD?
MLD, or Metachromatic Leukodystrophy, is a rare genetic disease that impacts the brain and nervous system, making it difficult for a child to move, speak, and think over time.
What is gene therapy?
Gene therapy is a medical treatment that tries to correct the underlying cause of a disease by changing or replacing faulty genes in the body's cells.
How is Libmeldy given?
Libmeldy is given as a single infusion (like a drip) after your child has received a special preparation called 'conditioning regimen' to prepare their body for the new cells.
How long will the study last?
The main part of the study will track your child for at least 24 months (two years) after the treatment, with some assessments possibly continuing for longer to monitor long-term effects.
What will researchers be looking for?
Researchers will be primarily checking how your child's movement and physical abilities change over time. They will also monitor brain health, nerve function, and overall safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.